WCM/EADO 2021 | Immunotherapies for satellite or ITM melanoma

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the use of immunotherapies for the treatment of satellite or in-transit metastases (ITM) of melanoma. Dr van Akkooi summarizes the findings of an analysis of trials of ipilimumab, nivolumab and pembrolizumab which attempted to identify patients with ITM within these trials. The study reported that patients with ITM could not be identified. Dr van Akkooi highlights the need for more clinical trials in this specific group of patients. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.